Berry Genomics Co.,Ltd reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 1,053.34 million compared to CNY 1,112.5 million a year ago. Revenue was CNY 1,053.34 million compared to CNY 1,112.5 million a year ago.

Net loss was CNY 16.19 million compared to net income of CNY 28.04 million a year ago. Basic loss per share from continuing operations was CNY 0.0458 compared to basic earnings per share from continuing operations of CNY 0.0791 a year ago. Diluted loss per share from continuing operations was CNY 0.0458 compared to diluted earnings per share from continuing operations of CNY 0.0791 a year ago.